Conversion from calcineurin inhibitors to sirolimus for chronic renal allograft dysfunction: A systematic review of the evidence

Transplantation

Volumn 82, Issue 9, 2006, Pages 1153-1162

  Mulay, Atul V ^a   Cockfield, Sandra ^b   Stryker, Rod ^a   Fergusson, Dean ^a   Knoll, Greg A ^a,c  

^a OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

^c UNIVERSITY OF OTTAWA   (Canada)

Author keywords

Calcineurin inhibitor; Chronic allograft nephropathy; Kidney transplantation; Meta analysis; Sirolimus; Systematic review

Indexed keywords

CALCINEURIN INHIBITOR; CHOLESTEROL; EVEROLIMUS; RAPAMYCIN; TRIACYLGLYCEROL;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ABNORMALLY LOW SUBSTRATE CONCENTRATION IN BLOOD; ABSCESS; ACNE; ALLERGIC REACTION; ANEMIA; CHOLESTEROL BLOOD LEVEL; CONFIDENCE INTERVAL; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DIARRHEA; DIGESTIVE SYSTEM FUNCTION DISORDER; DRUG ERUPTION; DRUG SAFETY; DRUG WITHDRAWAL; EYELID EDEMA; FATIGUE; FOLLOW UP; GRAFT REJECTION; HEPATITIS; HUMAN; KIDNEY DYSFUNCTION; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; LEUKOCYTE COUNT; LEUKOPENIA; MOUTH ULCER; NONHUMAN; PANCREATITIS; PNEUMONIA; PRIORITY JOURNAL; PROTEINURIA; PRURITUS; RENAL GRAFT DYSFUNCTION; REVIEW; STROKE; TASTE DISORDER; THROMBOCYTE COUNT; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL; WOUND HEALING;

CALCINEURIN; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; RANDOMIZED CONTROLLED TRIALS; SIROLIMUS;

EID: 33750991068     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.tp.0000237101.58974.43     Document Type: Review

References (75)

1. US Renal data system. US Renal Data System: Excerpts from the USRDS 2003 Annual Data Report: Atlas of End-Stage Renal Disease in the United States. Am J Kidney Dis 2003; 42: s1-s230.
2. Wolfe RA, Ashby VB, Milford EL, et al. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N Engl J Med 1999; 341: 1725.
3. Laupacis A, Keown P, Pus N, et al. A study of the quality of life and cost-utility of renal transplantation. Kidney Int 1996; 50: 235.
4. Ojo AO, Hanson JA, Wolfe RA, et al. Long-term survival in renal transplant recipients with graft function. Kidney Int 2000; 57: 307.
5. Chapman JR. Longitudinal analysis of chronic allograft nephropathy: clinicopathologic correlations. Kidney Int 2005; S108-S112.
6. Kaplan B, Meier-Kriesche HU. Death after graft loss: an important late study endpoint in kidney transplantation. Am J Transplant 2002; 2: 970.
7. Knoll G, Muirhead N, Trpeski L, et al. Patient survival following renal transplant failure in Canada. Am J Transplant 2005; 5: 1719.
8. USRDS. United States Renal Data System. Accessed February 13, 2006. www.usrds.org
9. Halloran PF, Melk A, Barth C. Rethinking Chronic Allograft Nephropathy: The Concept of Accelerated Senescence. J Am Soc Nephrol 1999; 10: 167.
10. Morales JM. Immunosuppressive treatment and progression of histologic lesions in kidney allografts. Kidney Int Suppl 2005; S124-S130.
11. Nankivell BJ, Borrows RJ, Fung CL, et al. The natural history of chronic allograft nephropathy. N Engl J Med 2003; 349: 2326.
12. Paul LC. Chronic allograft nephropathy: An update. Kidney Int 1999; 56: 783.
13. Sarnak MJ, Levey AS, Schoolwerth AC, et al. Kidney Disease as a Risk Factor for Development of Cardiovascular Disease: A Statement From the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 2003; 108: 2154.
14. de Mattos A, Olyaei A, Bennett W. Nephrotoxicity of immunosuppressive drugs: Long-term consequences and challenges for the future. Am J Kidney Dis 2000; 35: 333.
15. Joosten S, van Kooten C, Paul L. Pathogenesis of chronic allograft rejection. Transplant Int 2003; 16: 137.
16. Weir MR, Blahut S, Drachenburg C, et al. Late calcineurin inhibitor withdrawal as a strategy to prevent graft loss in patients with suboptimal kidney transplant function. Am J Nephrol 2004; 24(4): 379.
17. Suwelack B, Gerhardt U, Hohage H. Withdrawal of Cyclosporine or Tacrolimus After Addition of Mycophenolate Mofetil in Patients With Chronic Allograft Nephropathy. Am J Transplant 2004; 4: 655.
18. Morales JM, Andres A, Rengel M, Rodicio JL. Influence of cyclosporin, tacrolimus and rapamycin on renal function and arterial hypertension after renal transplantation. Nephrol Dial Transplant 2001; 16: 121.
19. Saunders RN, Metcalfe MS, Nicholson ML. Rapamycin in transplantation: A review of the evidence. Kidney Int 2001; 59: 3.
20. Dominguez J, Mahalati K, Kiberd B, et al. Conversion to rapamycin immunosuppression in renal transplant recipients: report of an initial experience. Transplantation 2000; 70: 1244.
21. Wyzgal J, Paczek L, Senatorski G, et al. Sirolimus rescue treatment in calcineurin-inhibitor nephrotoxicity after kidney transplantation. Transplant Proc 2002; 34: 3185.
22. Stallone G, Infante B, Schena A, et al. Rapamycin for treatment of chronic allograft nephropathy in renal transplant patients. J Am Soc Nephrol 2005; 16: 3755.
23. Schena FP, Wali RK, Pascoe MD, et al. Efficacy and safety of conversion from calcineurin inhibitors to sirolimus versus continued use of calcineurin inhibitors in renal allograft recipients: 12-month results from a large, randomized, open label, comparative trial [Abstract]. Available at: http://www.asn-online.org/home.aspx. Accessed October 12, 2005.
24. Schena FP, Wali RK, Pascoe MD, et al. A Randomized, open label, comparative evaluation of the safety and efficacy of conversion from calcineurin inhibitors to sirolimus versus continued use of calcineurin inhibitors in renal allograft recipients [Abstract]. Transpl Int 2005; 18 (Suppl 1): 155.
25. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996; 17(1): 1.
26. Watson CJ, Firth J, Williams PF et al. A Randomized Controlled Trial of Late Conversion from CNI-Based to Sirolimus-Based Immunosuppression Following Renal Transplantation. Am J Transplant 2005; 5: 2496.
27. Deeks JJ, Altman DG, Bradburn MJ. Statistical methods for examining heterogeneity and combining results from several studies in meta-analysis. In: Egger MD-SGADG, ed. Systematic Reviews in Health Care. BMJ Publishing Group, 2001; 285-312.
28. Newcombe RG. Two-sided confidence intervals for the single proportion: comparison of seven methods. Stat Med 1998; 17(8): 857.
29. Zhou XH, Brizendine EJ, Pritz MB. Methods for combining rates from several studies. Stat Med 1999; 18(5): 557.
30. Amm J, Ramamurthy G, Degala A, et al. Rapamycin substitution for calcineurin inhibitors in renal transplant recipients with chronic allograft nephropathy [Abstract]. Am J Transplant 2003; 3 (S5): 211.
31. Renders L, Steinbach R, Valerius T, et al. Low-dose sirolimus in combination with mycophenolate mofetil improves kidney graft function late after renal transplantation and suggests pharmacokinetic interaction of both immunosuppressive drugs. Kidney Blood Press Res 2004; 27: 181.
32. Baboolal K. Six month interim analysis of a phase III prospective, randomised study to compare conversion from calcineurin inhibitors to rapamycin in established renal allograft recipients with mild to moderate renal insufficiency [Abstract]. Am J Transplant 2004; 4 (S8): 220.
33. Citterlo F, Scata MC, Violi P, et al. Rapid conversion to sirolimus for chronic progressive deterioration of the renal function in kidney allograft recipients. Transplant Proc 2003; 35: 1292.
34. Crowley KL, Hardinger KL, Koch M, et al. A single center experience with sirolimus conversion therapy in renal allograft recipients [Abstract]. Am J Transplant 2003; 3 (S5): 354.
35. Diekmann F, Waiser J, Fritsche L, et al. Conversion to rapamycin in renal allograft recipients with biopsy-proven calcineurin inhibitor-induced nephrotoxicity. Transplant Proc 2001; 33: 3234.
36. Diekmann F, Budde K, Oppenheimer F, et al. Predictors of success in conversion from calcineurin inhibitor to sirolimus in chronic allograft dysfunction. Am J Transplant 2004; 4: 1869.
37. Egidi MF, Cowan PA, Naseer A, Gaber AO. Conversion to sirolimus in solid organ transplantation: a single-center experience. Transplant Proc 2003; 35: 131S.
38. Guasch A, Near M, Selvaraj S. Determinants of long term preservation of renal function after conversion to sirolimus in patients with chronic allograft nephropathy [Abstract]. Am J Transplant 2004; 4(S8): 266.
39. Hadaya K, Wissing M, Broeders N, Abramowicz D. Nephrotic range proteinuria and other severe adverse events after conversion to sirolimus in renal transplantation: Is high exposure to sirolimus responsible? [Abstract]. Am J Transplant 2004; 4(S8): 433.
40. Letavernier E, Peraldi M, Kreis H, Legendre C. Proteinuria following switch from calcineurin inhibitors to sirolimus: A retrospective study [Abstract]. Am J Transplant 2004; 4(S8): 161.
41. Lord H, Boucher A, Morin M, Dandavino R. Late conversion to sirolimus in a kidney transplant population: Is it worth? [Abstract]. Am J Transplant 2004; 4 (S8): 221.
42. Paczek L, Dedochova J, Matl I, Pohanka E. An open non comparative pilot study of renal function after conversion from cyclosporin (CsA) to sirolimus (SRL) in stable renal allograft recipients with mild to moderate renal insufficiency [Abstract]. Am J Transplant 2003; 3 (S5): 217.
43. Peddi VR, Jensik S, Pescovitz M, et al. An open-label pilot study evaluating the safety and efficacy of converting from calcineurin inhibitors to sirolimus in established renal allograft recipients with moderate renal insufficiency. Clin Transplant 2005; 19: 130.
44. Sankaranarayanan N, Balarezo F, Alleman K, et al. Chronic allograft damage index (CADI)2 scoring at conversion from calcineurin inhibitors (CI) to sirolimus predicts renal outcome in kidney transplant recipients[Abstract]. Am J Transplant 2004; 4 (S8): 296.
45. Thaunat O, Lechaton, Mamzer M, et al. Late introduction of sirolimus introduces anemia of inflammatory state in renal transplant recipients. [Abstract]. Am J Transplant 2005; 5 (S11): 554.
46. van Gelder T, ter Meulen CG, Hene R, et al. Oral ulcers in kidney transplant recipients treated with sirolimus and mycophenolate mofetil. Transplantation 2003; 75: 788.
47. Wali RK, Richards A, Cunningham R, et al. Can we change the progressive decay in graft function after the onset of chronic allograft nephropathy (CAN) in the recipients of kidney allografts? (preliminary results of the ongoing study) [Abstract]. Am J Transplant 2003; 3 (S5): 336.
48. Sundberg AK, Rohr MS, Hartmann EL, et al. Conversion to sirolimus-based maintenance immunosuppression using daclizumab bridge therapy in renal transplant recipients. Clin Transplant 2004; 18: 61.
49. Moneim HA, Fletchner SM, George P, et al. Conversion to and from sirolimus in renal and hepatic transplant recipients treated with calcineurin inhibitors:Effect on renal function.[Abstract]. Am J Transplant 2005; 5(S11): 376.
50. Lacha J, Bartosova K, Matl I, et al. Sirolimus associated proteinuria. Study in kidney (KTx) and heart (HTx) recipients after calcineurin inhibitor (CNI) withdrawal and in KTX with sirolimus de novo immunosuppression [Abstract]. Am J Transplant 2005; 5: 414.
51. Hoecker B, Feneberg R, Koepf S, et al. Switch of immunosuppression from calcineurin inhibitors (CNI) to sirolimus (SRL) in pediatric renal transplant recipients with CNI toxicity [Abstract]. Am J Transplant 2005; 5(S11): 497.
52. Ruiz JC, Diekmann F, Campistol JM, et al. Evolution of proteinuria after conversion from calcineurin inhibitors (CNI) to sirolimus (SRL) in renal transplant patients. A multicenter study [Abstract]. Am J Transplant 2005; 5(S11): 519.
53. Wu M-S, Chang C-T, Hung C-C. Rapamycin in patients with chronic renal allograft dysfunction. Clin Transplant 2005; 19: 236.
54. Bumbea V, Kamar N, Ribes D, et al. Long term results in renal transplant patients with allograft dysfunction after switching from calcineurin inhibitors to sirolimus. Nephrol Dial Transplant 2005; 20: 2517.
55. Johny KV, Nampoory MR, Hamid MH, et al. Low-dose sirolimus in combination with mycophenolate in calcineurin inhibitor elimination: the Kuwaiti experience. Transplant Proc 2003; 35: 2750.
56. Schnuelle P, van der Heide JH, Tegzess A, et al. Open Randomized Trial Comparing Early Withdrawal of either Cyclosporine or Mycophenolate Mofetil in Stable Renal Transplant Recipients Initially Treated with a Triple Drug Regimen. J Am Soc Nephrol 2002; 13: 536.
57. Morelon E, Kreis H. Sirolimus therapy without calcineurin inhibitors: Necker Hospital 8-year experience. Transplant Proc 2003; 35: 52S.
58. Dittrich E, Schmaldienst S, Soleiman A, et al. Rapamycin-associated post-transplantation glomerulonephritis and its remission after reintroduction of calcineurin-inhibitor therapy. Transplant Int 2004; 17: 215.
59. Butani L. Investigation of pediatric renal transplant recipients with heavy proteinuria after sirolimus rescue. Transplantation 2004; 78: 1362.
60. Senior PA, Paty BW, Cockfield SM, et al. Proteinuria developing after clinical islet transplantation resolves with sirolimus withdrawal and increased tacrolimus dosing. Am J Transplant 2005; 5: 2318.
61. Saurina A, Campistol JM, Piera C, et al. Conversion from calcineurin inhibitors to sirolimus in chronic allograft dysfunction: changes in glomerular haemodynamics and proteinuria. Nephrol Dial Transplant 2006; 21: 488.
62. Myers BD, Sibley R, Newton L et al. The long-term course of cyclosporine-associated chronic nephropathy. Kidney Int 1988; 33: 590.
63. McTaggart RA, Gottlieb D, Brooks J, et al. Sirolimus Prolongs Recovery from Delayed Graft Function After Cadaveric Renal Transplantation. Am J Transplant 2003; 3: 416.
64. Fervenza FC, Fitzpatrick PM, Mertz J, et al. Acute rapamycin nephrotoxicity in native kidneys of patients with chronic glomerulopathies. Nephrol Dial Transplant 2004; 19: 1288.
65. Roodnat JI, Mulder PG, Rischen-Vos J, et al. Proteinuria after renal transplantation affects not only graft survival but also patient survival. Transplantation 2001; 72: 438.
66. Kasiske BL, Chakkera HA, Louis TA, Ma JZ. A Meta-Analysis of Immunosuppression Withdrawal Trials in Renal Transplantation. J Am Soc Nephrol 2000; 11: 1910.
67. Johnson RW, Kreis H, Oberbauer R, et al. Sirolimus allows early cyclosporine withdrawal in renal transplantation resulting in improved renal function and lower blood pressure. Transplantation 2001; 72: 777.
68. Chueh SC, Kahan BD. Dyslipidemia in renal transplant recipients treated with a sirolimus and cyclosporine-based immunosuppressive regimen: incidence, risk factors, progression, and prognosis. Transplantation 2003; 76: 375.
69. Booth JC, Joseph JT, Jindal RM. Influence of hypercholesterolemia on patient and graft survival in recipients of kidney transplants. Clinical Transplant 2003; 17: 101.
70. Roodnat JI, Mulder PG, Zietse R, et al. Cholesterol as an independent predictor of outcome after renal transplantation. Transplantation 2000; 69: 1704.
71. Ponticelli C, Villa M, Cesana B, et al. Risk factors for late kidney allograft failure. Kidney International 2002; 62: 1848.
72. Blum CB. Effects of sirolimus on lipids in renal allograft recipients: an analysis using the Framingham risk model. Am J Transplant 2002; 2: 551.
73. Kauffman HM, Cherikh WS, Cheng Y, et al. Maintenance immunosuppression with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo malignancies. Transplantation 2005; 80: 883.
74. USRDS Annual Data Report, 2005. Available at http://www.usrds.org/2005/ pdf/07_tx_05.pdf. Accessed September 21, 2006.
75. Halloran PF. Call for revolution: A new approach to describing allograft deterioration. Am J Transplant 2002; 2: 195.